Stock Analiz

Scienture Holdings, Inc. SCNX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$2.90Market cap $5M
Open the interactive analysis →

Scienture Holdings, Inc. (SCNX) is a healthcare company listed in the US with a market value of about $5M. In the twelve months to June 30, 2026 it had revenue of $821315 and net income of -$38M, a net margin of -4620.9%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -52% a year, a 5-year average ROIC of -61%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About Scienture

Scienture is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2014 to $431609 in 2025, a decline of about 10.7% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 2609% over three years (dilution for shareholders). It spends 453% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.8
P/B0.1
EV/EBITDA—
PEG—
Dividend yield—
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-52.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2753.5%
ROIC (5-yr avg.)-60.6%
Profitable years (of last 10)3
Years paying a dividend1

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$821315$431609—$1M$10M$10M$17M$7M$4M$3M$2M
Net income-$38M-$42M$9M-$18M-$3M-$5M-$3M-$284428$9038$288983-$3M
Free cash flow——-$14M—-$2M-$3M-$2M$59523$258380——
EPS (diluted)$-2.10$-2.70$2.48$-23.35$-6.13$-0.65$-0.33$-0.05$0.00$0.06$-0.54
Net margin-4620.9%-9618.0%—-1308.3%-33.9%-53.8%-14.8%-3.8%0.2%9.9%-111.2%
ROIC—-57.9%-17.4%-45.4%-98.7%-83.3%-21.8%1.9%-5.1%88.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Scienture stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Scienture pay a dividend?

Not currently.

Is Scienture a good stock to buy?

We do not give buy or sell advice. Scienture scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.